Initiating Inclisiran Early Leads to Significantly Better Long-Term LDL Reduction Compared to Usual Care in Patients with Atherosclerotic Cardiovascular Disease
Initiating the cholesterol-lowering drug inclisiran earlier in the treatment pathway leads to significantly better long-term low-density lipoprotein (LDL) reduction compared to usual care in patients with atherosclerotic cardiovascular disease (ASCVD).